TP53 and acute myeloid leukemia: To test this in vivo, we engrafted wt p53 human AML primary cells in non-obese diabetic/severe combined immunodeficient (NOD/SCID)-interleukin-2 receptor γ null (NSG) mice following our previous protocol [42, 43].